Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients.
Spreafico
M
M
Peyvandi
F
F
Pizzotti
D
D
Moia
M
M
Mannucci
P M
PM
D000074:Acenocoumarol / Q000008:administration & dosage / Q000627:therapeutic use*; D000483:Alleles; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007558:Italy; D016133:Polymerase Chain Reaction; D013923:Thromboembolism / Q000235:genetics* / Q000517:prevention & control; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000074:Acenocoumarol